Managers / Q2 2021 · view latest →
Vida Ventures Advisors, LLC
CIK 0001831423 · 40 BROAD STREET, SUITE 201, BOSTON, MA, 02109 · 6176489100
Summary
Vida Ventures Advisors, LLC reported $399M in U.S.-listed holdings across 9 positions for Q2 2021.
The portfolio is heavily concentrated: 260 alone accounts for 21.9% of reported value.
Compared with Q1 2021, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 64.3% · $256M
- ADR · 21.9% · $87M
- Other · 13.8% · $55M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| 260Centessa Pharmaceuticals plc | NEW | +3.93M | 3.93M | +$87M | $87M |
| OYSTOyster Point Pharma, Inc. | TRIMMED | −120.0K | 658.5K | −$3M | $11M |
| Assembly Biosciences, Inc. | TRIMMED | −65.4K | 384.6K | −$578,000 | $1M |
| Praxis Precision Medicines, Inc. | HELD | +0 | 2.94M | −$43M | $54M |
| KNTEUSDKinnate Biopharma, Inc. | HELD | +0 | 2.75M | −$22M | $64M |
| ALLOAllogene Therapeutics, Inc. | HELD | +0 | 1.80M | −$17M | $47M |
| DYNDyne Therapeutics, Inc. | HELD | +0 | 2.96M | +$16M | $62M |
| KRON1USDKronos Bio, Inc. | HELD | +0 | 2.77M | −$15M | $66M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | 260Centessa Pharmaceuticals plchistory → | Ordinary Shares | 21.90% | $87M | 3.93M |
| 2 | KRON1USDKronos Bio, Inc.history → | Common Stock | 16.61% | $66M | 2.77M |
| 3 | KNTEUSDKinnate Biopharma, Inc.history → | Common Stock | 16.04% | $64M | 2.75M |
| 4 | DYNDyne Therapeutics, Inc.history → | Common Stock | 15.62% | $62M | 2.96M |
| 5 | Praxis Precision Medicines, Inc. | Common Stock | 13.47% | $54M | 2.94M |
| 6 | ALLOAllogene Therapeutics, Inc.history → | Common Stock | 11.76% | $47M | 1.80M |
| 7 | OYSTOyster Point Pharma, Inc.history → | Common Stock | 2.84% | $11M | 658.5K |
| 8 | Homology Medicines, Inc. | Common Stock | 1.41% | $6M | 770.8K |
| 9 | Assembly Biosciences, Inc. | Common Stock | 0.37% | $1M | 384.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $29M | 2 | Nov 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $16M | 2 | Jul 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $14M | 3 | Apr 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $146M | 6 | Jan 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $139M | 6 | Oct 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $91M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $180M | 5 | Apr 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $84M | 7 | Jan 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $65M | 8 | Oct 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $77M | 7 | Jul 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $73M | 7 | Apr 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $74M | 7 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $111M | 8 | Oct 5, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $118M | 8 | Jul 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $172M | 8 | May 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $267M | 8 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $349M | 8 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $399M | 9 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $396M | 8 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $487M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $160M | 5 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.